ShareValue scores for CERO: Valuation 49, Quality 50, Growth 47, Health 35.
CERONASDAQ
CERo Therapeutics Holdings, Inc. Common Stock
$0.01
(+11.11%)
CERONASDAQ
CERo Therapeutics Holdings, Inc. Common Stock
$0.01(+11.11%)
Loading chart...
Sentiment
Verdicts
Value:Fair Value
Quality:Moderate
Growth:Moderate
Health:Stressed
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
3% to 16%
Rating
Trap Risk
Return
3% to 16%
Valuation
49
Fair Value
Price vs Value
Quality
50
Moderate
Business Strength
Growth
47
Moderate
Revenue & Earnings
Health
35
Stressed
Financial Stability
Momentum
17
Bearish
Price Trend
Company Details
About
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Market Cap$406,012
P/E RatioN/A
Dividend YieldNone
Sector Rank#2035
Score Analysis
AI Investment Thesis
Data as of:Aug 7, 2026
|Last calculated:Aug 7, 2026